Introduction
The burden and composition of atherosclerotic coronary plaques provide important diagnostic and prognostic information.
1,2 Statin therapy reduces both circulating lipid levels and cardiovascular events in patients with coronary artery disease (CAD). 3 Serial intracoronary imaging studies assessing the effect of statin therapy on coronary plaques have confirmed favourable morphological changes including significant regression of total plaque volume (TPV) and lipid composition. [4] [5] [6] Coronary computed tomographic angiography (CCTA) has become a clinically established imaging method that allows for noninvasive identification of coronary artery atherosclerosis and reliable characterization and quantification of coronary plaque. 7, 8 In addition to calcified plaque characterization, CCTA allows for accurate description of non-calcified plaque (NCP) types including adverse plaque characteristics (APC), low attenuation plaques (LAP), spotty calcified plaques, and positive remodelling. 7 Plaque volume and APC determined by CCTA are associated with presence of lesion-specific ischaemia. 9 , 10 The ability of CCTA in differentiation of plaque tissue characteristics has been shown to be comparable to intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
11-13
The non-invasive nature and wide availability of CCTA makes it an attractive method to investigate serial morphological plaque changes. Consequently, results of studies using CCTA to assess the effect of statin therapy on plaque remodelling may contribute with important and additive information concerning risk stratification and for decision-making regarding the appropriate therapeutic choice in patients with CAD, with or without APC. Recently, several CCTA studies assessing the effect of statin therapy on coronary plaque morphology have been published. [14] [15] [16] Accordingly, we performed a systematic literature review and meta-analysis on the potential role of CCTA in assessing the remodelling impact of statin therapy on coronary plaque burden and composition.
Methods Design
A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for systematic review and Meta-analysis (PRISMA). 17 
Search strategy
The search was conducted in the electronic databases PubMed, EMBASE, and Cochrane library for all published studies that examined the effect of statins on coronary plaque composition using CCTA. The following keywords, in different combinations, were used: computed tomography (CT), angiography, coronary, plaque, and statin. Reference lists of relevant published reviews and all retrieved papers on this topic were screened as well. The literature search was restricted to published studies after year 2000 (after introduction of the multi-slice CT technique) and up to 1 May 2017.
Study eligibility
Randomized controlled trials (RCT) or observational studies reporting the effect of statin therapy alone on coronary plaque burden and/or composition at baseline and after follow-up period were eligible for inclusion. The following parameters defined by the studies were considered eligible: TPV, NCP volume, LAP volume [defined as Hounsfield unit (HU) <30] or lipid core volume, calcified plaque volume, and plaque signal density measured as HU. Eligible studies were required to provide values of plaque measurements both at baseline and follow-up. Studies not providing required data were excluded.
Intensive statin treatment was defined as achievement of substantial reduction of low density lipids (LDL) with a target level of 70 or 80 mg/dL either by increasing the statin dose or administration of a maximal statin dose. The moderate (usual care) dose receivers continued their usual dose without a minimum target level of LDL.
Data extraction and homogenization
All available demographic and methodological data, plaque types, and volumes reported as means and standard deviations (SD) were extracted from each included study. Values reported as medians with ranges were recalculated to their means with SDs. Intensive and moderate statin therapy receiving arms were extracted as two independent arms. In case of lacking data, corresponding authors of studies were contacted concerning specific information. Primarily an experienced author (J.A.) conducted the literature search, study selection and data extraction that subsequently were confirmed by the first author (L. A.) . Any conflict was resolved by consensus.
Statistics
We used the weighted mean difference method for pooling of all means and their SDs for both statin-receiving and control arms. Similarly, total and LDL cholesterol values were pooled together. We pooled data of all statin-receiving patients in two independent intensive and moderate therapy arms vs. controls regardless of study type providing the weighted mean differences between follow-up and baseline values. Studies providing mean differences both in statin-receiving and controls were also pooled to calculate the magnitude of the differences at follow-up. Due to the insignificant heterogeneity between studies there were no differences between fixed and random effects models; however, in the analysis of TPV change we used fixed effects model to restore the true sizes of the included studies. We tested heterogeneity among studies using the v 2 method (with a P-value of 0.05 considered significant) and the I 2 statistic.
The I 2 indicated the percentage of variation between-study heterogeneity, where a value above 20% was considered significant. All analyses were performed using the meta-analysis package of the statistic software program STATA version 13 (STATA Corporation, Lakeway Drive, College Station, TX, USA).
Results

Results of the search
The search process and flow chart of results are shown in Figure 1 .
The search resulted in inclusion of 12 published studies ( Table 1) .
Characteristics of the included studies and patients
Two of the included studies were RCTs, 14, 16 five were nonrandomized observational studies with control arms 15, [18] [19] [20] [21] and five were observational studies without controls [22] [23] [24] [25] [26] (Table 1) .
A total of 792 patients were included. Of those, 199 patients received intensive statin therapy, 404 received moderate statin therapy, and 189 received no statin therapy (controls). The demographic features, follow-up periods and types of statins used are shown in Table 1 . Mean (±SD) age of the whole population was 62 ± 5 years, 78% were males, and mean (±SD) follow-up was 14.5 ± 9.5 months. There were no differences in mean age (P-value = 0.52) or percent of male gender (P-value = 0.83) between statin-receiving and control arms.
The risk profile of patients in the intensive statin therapy, moderate statin therapy and control groups showed a mean age of 61.5 ± 7.2, 61.1 ± 7.5, and 60.5 ± 7.2 years, percents of male gender were 71%, 71%, and 74%, hypertension 58%, 58%, and 51%, dyslipidaemia 57%, 49% and 47%, diabetes 35%, 21%, and 27% and current smoking 42%, 25%, and 36%, respectively. Differences between the three groups were not statistically significant.
Image acquisition and plaque assessment
CCTA images were acquired using different CT equipment and were transferred to a workstation with dedicated software for three-dimentional plaque analysis. Included patients received heart rate reducing medication (beta-blockers) and/or appropriate protocols were used to obtain optimal image quality. 27, 28 All studies reported that images or coronary segments of poor quality due to artefacts were excluded from analysis. Using semi-automated or automated software for plaque analysis 29 was reported in six studies. [14] [15] [16] 21, 24, 26 Plaque volumes were calculated after detection of outer and inner vessel outlines and if necessary were modified. Plaque types were identified using HUs. Two independent readers participated in plaque analysis in eight studies, 15, [18] [19] [20] [21] [22] [23] 26 one reader in two studies, 14, 16 while this was unclear in two studies. 24, 25 All readers were blinded to clinical data in nine studies, 8, [14] [15] [16] [18] [19] [20] [21] 23, 26 but this was unclear in three studies. 22, 24, 25 Two studies reported good both intra-and inter-observer agreement 14,15 using
Bland-Altman test and plots or table. One study showed good intra-observer agreement 23 of the measured volume (absolute difference divided by the mean value of both measurements) both at baseline and follow-up. The fourth study 18 that used two observers did not report inter-observer agreement.
The effect of statin therapy on TPV
Meta-analysis of data from ten studies [14] [15] [16] [18] [19] [20] [21] 23, 24, 26 showed that TPV decreased significantly by a weighted mean differences of - 20 Figure 2) . There was also a decrease in TPV in moderate statin therapy receivers, however this change did not reach statistical significance -1.67 (95% CI -9.99, 6.65; P = 0.69) mm 3 ( Figure 2 ). The percent of mean volume regression was -3.6%
and -0.4% in intensive and moderate statin receivers, respectively, vs. þ5.7% progression in controls. Analysis of mean differences provided by six studies 15, 16, [18] [19] [20] [21] showed that the magnitude of TPV decreased in statin therapy receivers regardless of dose intensity compared with controls was -30.4 (95% CI -41.6, -19.1; P < 0.001) mm 3 . Supplementary sensitivity analyses by excluding studies with possible heterogeneity showed that the results were unchanged after excluding the study by Lo et al. 16 on patients with human immunodeficiency virus. Moreover, a sensitivity analysis by stepwise exclusion of studies in both intensive and moderate dose groups showed that the results concerning the effect of statins remained unchanged and confirming that none of these studies had a dominant effect.
The effect of statin therapy on NCP volume
Meta-analysis of data from three studies 16, 18, 21 showed that NCP volume decreased in patients receiving statin therapy and increased in control patients; however, these changes were not statistically significant, -7.62 (95% CI -17.38, 2.13; P = 0.124) vs. 12 .04 (95% CI -1.78, 25.86 ; P = 0.088) mm 3 , respectively ( Figure 3) . The percent of mean volume regression was -9% in intensive statin therapy receivers vs. a progression of þ12% in controls. Analysis of mean differences between statin and control arms showed a significant plaque volume regression of -0.99 (95% CI -1.35, -0.62; P < 0.001) mm 3 in favour of patients receiving statin therapy.
The effect of statin therapy on LAP volume
Meta-analysis of data from five studies 15, [19] [20] [21] 24 showed that mean LAP volume decreased significantly in patients receiving statin therapy by 
The effect of statin therapy on calcified plaque volume and density
Meta-analysis of data from four studies 14, 16, 21, 23 showed that calcified plaque volume increased significantly in patients receiving statin but not significantly in controls 11.83 (95% CI 3.37, 20.29 ; P = 0.006) mm 3 vs. 5 .00 (95% CI -1.95, 11.98 ; P = 0.15) mm 3 ( Figure 5 ). The percent of mean volume progression was þ12.0% in patients receiving statin therapy vs. þ3.5% in controls. Metaanalysis of mean differences in statin receivers vs. controls in two studies 16, 21 showed no significant difference in calcified volume plaque progression with a difference of 4.1 (95% CI - 10.9, 19.20 ; P = 0.59) mm 3 .
Meta-analysis of four studies 14, 22, 24, 25 assessing changes in calcium density signal after statin therapy showed a significant increase by 21 .99 (95% CI 9.2, 34.8; P < 0.001) HU ( Figure 5 ). 
Changes in total and LDL cholesterol
In patients receiving statin therapy, the total cholesterol and LDL declined from 207 ± 14 and 125 ± 17 at baseline to 153 ± 24 and 74.5 ± 16 mg/dL at follow-up with estimated weighted mean differences of -62.4 (-64.8, -60.1) and -65.1 (-67.1, -63.1) mg/L, respectively (both P < 0.001). In intensive statin arms, a target level of LDL below 80 mg/dL was achieved.
Comparison of plaque changes with the previously published IVUS and OCT studies
An overview of results of from previously published meta-analyses on the effect of statin therapy on coronary plaque composition assessed with IVUS and OCT compared to the results of the current meta-analysis using CCTA are shown in Table 2 . 
Type of CT scanners and estimated effective radiation dose
Two studies used new generation dual-source CT scanners, 15, 24 while the majority of the remaining studies used 64-slice scanners. The effective radiation dose was reported in four studies. One study used retrospective gating and reported a mean effective radiation dose of 17 ± 5 mSv. 23 Three studies, including two studies with dual-source CT, reported a mean effective radiation dose of 6.6 ± 1.5 mSv.
14,15,24
Discussion
This systematic review and meta-analysis provided an updated overview of the published studies assessing the impact of statin therapy on different coronary plaque volumes and composition determined by CCTA. Intensive statin therapy was associated with regression in TPV and LAP volume. Moderate statin therapy was not followed by significant changes in TPV. Statin therapy was associated with increase in calcified plaque volume and calcium signal intensity as well. On contrary, no statin therapy displayed progression in TPV and LAP volume without any significant increase in calcified plaque volume. These volumetric and compositional plaque changes associated with a substantial fall in total cholesterol and LDL levels supported a causal and plaque stabilizing effect of statin therapy. The findings of this study are in agreement with a previously published meta-analyses using IVUS to assess the effect of statin therapy on coronary plaque volumes, whereas a significant reduction in TPV was reported during an average of 18 months. 4 Another metaanalysis showed that statins besides atherosclerotic plaque volume regression, also promoted atheromatic calcification by mounting calcium density. 5 Noteworthy, a close relationship between LDL reduction and atheroma regression was also demonstrated. However, no reduction in LAP volume in the IVUS studies was observed. These discrepancies between CCTA and IVUS findings may be due to differences in determinants of outcomes such as patient characteristics, lack of statistical power of the included studies, or finally due to technical failure of IVUS to accurately identify lipid pool and necrotic core. OCT studies have demonstrated a significant increase in fibrous cap thickness (FCT) at expense of a decrease in LAP volume after statin therapy. 30 Due to the low tissue penetration, OCT cannot reliably assess TPV, but its high resolution allows for accurate assessment of the fibrous cap. 32 Recent OCT studies support the stabilizing effect of statins by increasing the FCT and diminishing plaque lipid arc and length. 6, 31 Identification of LAP and plaque rupture assessed with CCTA has been confirmed to be comparable to the aforementioned FCT changes identified by OCT. 13 Thus, the volume reduction of LAP assessed with CCTA and OCT, but not with IVUS, may in fact mirror the differences in the technical abilities of these modalities to visualize plaque tissue characteristics. 32 These findings may further suggest that plaque remodelling is a complicated process that may favourably be assessed by an integrated multi-modality imaging approach.
The mechanism explaining the beneficial changes of statin therapy on plaque morphology and, ultimately, improved cardiovascular outcome is most likely due to its LDL-lowering effect. Although potential pleiotropic effects of statin therapy have been proposed, recent large-scale randomized trials with novel LDL-lowering therapies have shown relative risk reductions per mmol/L fall in LDL comparable to that of statin therapy. 33, 34 Adding a PCSK9-inhibitor to statin therapy has shown to reduce both LDL and TPV beyond that achieved by statins alone. 35 However, large-scale prognostic trials using appropriate plaque imaging modalities including CCTA are warranted to better clarify the mechanisms responsible for the compositional plaque changes accompanied by lipid-lowering therapies. Except for two studies all studies in this review used older generations of CT scanners. The new generations of CT scanners using radiation saving technologies have substantially reduced the effective radiation dose even below 1 mSv, making it ethically acceptable to conduct serial CCTA studies.
36,37
Limitations
The studies included in this review were of small sizes and most of them were of observational nature. The studies were also characterized by substantial heterogeneity concerning baseline populations, study design, types of statins used, and length of follow-up period. Moreover, included studies did not directly compare CCTA plaque evaluation vs. a reference method. Only two studies reported coronary calcium score and therefore an analysis on this parameter was irrelevant. In some studies, it was unclear whether the readers were blinded to clinical data or inter-observer evaluation was performed. The included studies did not directly compare CCTA plaque evaluation vs. a reference method. Therefore, the results of this study should be interpreted cautiously.
Conclusions and perspectives
Initial studies demonstrated the potential role of CCTA in evaluating the effect of statin therapy on plaque volume and composition. The possible plaque stabilizing effect of statins seems dose-related. Future trials implicating advanced CCTA technologies with higher resolution are required to explain further mechanisms behind compositional plaque changes following use of anti-atherosclerotic therapies.
